# Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.

> **NCT04911517** · PHASE2 · UNKNOWN · sponsor: **Beijing Friendship Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **COMBINATION_PRODUCT:** long course radiotherapy + capecitabine + PD-1 monoclonal antibody treatment combinations

## Key facts

- **NCT ID:** NCT04911517
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-06-01
- **Primary completion:** 2022-12
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-02-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04911517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04911517, "Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by TME for LARC.". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04911517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*